Literature DB >> 19747137

Cardiovascular effects of losartan and its relevant clinical application.

Feichao Xu1, Caiping Mao, Yali Hu, Can Rui, Zhice Xu, Lubo Zhang.   

Abstract

The renin-angiotensin system (RAS) plays an important role in the homeostasis of the cardiovascular system and in the development of cardiovascular diseases. An abnormal expression or over activation of the local RAS in the heart and vasculature system is one of the most common mechanisms in pathophysiological processes in cardiovascular diseases. This also provides a basis for medical prevention and treatments using chemical approaches. Losartan is a selective nonpeptite antagonist against type 1 angiotensin II receptors (AT1R), and has been applied in medical treatments of a variety of cardiovascular diseases, including essential hypertension. This article reviews direct and indirect cardiovascular effects of losartan on the heart and blood vessels. It summarizes the chemical basis of AT1R for the action site of losartan,focuses on the mechanisms underlying the action of losartan involved in both the heart and vasculature, and reviews the information that may be helpful in the development of new chemical candidates or approaches in the war against cardiovascular diseases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19747137      PMCID: PMC2888651          DOI: 10.2174/092986709789178046

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  235 in total

1.  Angiotensin-(1-7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects.

Authors:  Michikado Iwata; Randy T Cowling; Devorah Gurantz; Cristina Moore; Shen Zhang; Jason X-J Yuan; Barry H Greenberg
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-07-15       Impact factor: 4.733

2.  Regional changes in angiotensin II receptor density after experimental myocardial infarction.

Authors:  D C Lefroy; J Wharton; T Crake; G A Knock; R A Rutherford; T Suzuki; K Morgan; J M Polak; P A Poole-Wilson
Journal:  J Mol Cell Cardiol       Date:  1996-02       Impact factor: 5.000

Review 3.  Is angiotensin II a proliferative factor of cardiac fibroblasts?

Authors:  Fatiha Bouzegrhane; Gaétan Thibault
Journal:  Cardiovasc Res       Date:  2002-02-01       Impact factor: 10.787

4.  Angiotensin II (type-1) receptor locus: CA repeat polymorphism and genetic mapping.

Authors:  E Davies; A Bonnardeaux; G M Lathrop; P Corvol; E Clauser; F Soubrier
Journal:  Hum Mol Genet       Date:  1994-05       Impact factor: 6.150

5.  Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy.

Authors:  H Watkins; A Rosenzweig; D S Hwang; T Levi; W McKenna; C E Seidman; J G Seidman
Journal:  N Engl J Med       Date:  1992-04-23       Impact factor: 91.245

Review 6.  Molecular and cellular mechanisms in vascular injury in hypertension: role of angiotensin II.

Authors:  Rhian M Touyz
Journal:  Curr Opin Nephrol Hypertens       Date:  2005-03       Impact factor: 2.894

Review 7.  Molecular determinants of peptide and non-peptide binding to the AT1 receptor.

Authors:  S S Karnik; A Husain; R M Graham
Journal:  Clin Exp Pharmacol Physiol Suppl       Date:  1996

8.  Renin-angiotensin system in stretch-induced hypertrophy of cultured neonatal rat heart cells.

Authors:  S Miyata; T Haneda; J Osaki; K Kikuchi
Journal:  Eur J Pharmacol       Date:  1996-06-20       Impact factor: 4.432

Review 9.  Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases.

Authors:  H Matsubara
Journal:  Circ Res       Date:  1998 Dec 14-28       Impact factor: 17.367

10.  Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways.

Authors:  Sophie Cardin; Danshi Li; Nathalie Thorin-Trescases; Tack-Ki Leung; Eric Thorin; Stanley Nattel
Journal:  Cardiovasc Res       Date:  2003-11-01       Impact factor: 10.787

View more
  9 in total

1.  Foetal hypoxia increases cardiac AT(2)R expression and subsequent vulnerability to adult ischaemic injury.

Authors:  Qin Xue; Chiranjib Dasgupta; Man Chen; Lubo Zhang
Journal:  Cardiovasc Res       Date:  2010-09-23       Impact factor: 10.787

2.  Maternal high-salt intake during pregnancy reprogrammed renin-angiotensin system-mediated cardiomyocyte apoptosis in the adult offspring heart.

Authors:  Juanxiu Lv; Peiwen Zhang; Yujuan Zhang; Hanzhe Kuang; Li Cao; Conglong Wu; Lin Jiang; Dawei Li; Caiping Mao; Zhice Xu
Journal:  Reprod Sci       Date:  2013-05-20       Impact factor: 3.060

3.  Changed salt appetite and central angiotensin II-induced cellular activation in rat offspring following hypoxia during fetal stages.

Authors:  Weili Yang; Caiping Mao; Fei Xia; Jianli Zheng; Aiqing Wang; Liyan Zhu; Rui He; Zhice Xu
Journal:  Peptides       Date:  2010-03-20       Impact factor: 3.750

4.  Angiotensin II receptor I blockade prevents stenosis of tissue engineered vascular grafts.

Authors:  Juan de Dios Ruiz-Rosado; Yong-Ung Lee; Nathan Mahler; Tai Yi; Frank Robledo-Avila; Diana Martinez-Saucedo; Avione Y Lee; Toshihiro Shoji; Eric Heuer; Andrew R Yates; Jordan S Pober; Toshiharu Shinoka; Santiago Partida-Sanchez; Christopher K Breuer
Journal:  FASEB J       Date:  2018-06-15       Impact factor: 5.191

5.  A randomized, double blind, placebo-controlled, multicenter phase II trial of Allisartan Isoproxil in essential hypertensive population at low-medium risk.

Authors:  Ying Li; Xiao-hui Li; Zhi-jun Huang; Guo-ping Yang; Guo-gang Zhang; Shui-ping Zhao; Ying Guo; Shi-juan Lu; Jian-lin Ma; Fan-bo Meng; Ping Chen; Hong Yuan
Journal:  PLoS One       Date:  2015-02-18       Impact factor: 3.240

6.  Synthesis and Evaluation of [18F]FEtLos and [18F]AMBF3Los as Novel 18F-Labelled Losartan Derivatives for Molecular Imaging of Angiotensin II Type 1 Receptors.

Authors:  Martha Sahylí Ortega Pijeira; Paulo Sérgio Gonçalves Nunes; Sofia Nascimento Dos Santos; Zhengxing Zhang; Arian Pérez Nario; Efrain Araujo Perini; Walter Miguel Turato; Zalua Rodríguez Riera; Roger Chammas; Philip H Elsinga; Kuo-Shyan Lin; Ivone Carvalho; Emerson Soares Bernardes
Journal:  Molecules       Date:  2020-04-18       Impact factor: 4.411

7.  Comparison of the GPVI inhibitors losartan and honokiol.

Authors:  Marie-Blanche Onselaer; Magdolna Nagy; Chiara Pallini; Jeremy A Pike; Gina Perrella; Lourdes Garcia Quintanilla; Johannes A Eble; Natalie S Poulter; Johan W M Heemskerk; Steve P Watson
Journal:  Platelets       Date:  2019-03-08       Impact factor: 3.862

8.  Effects of Captopril and Losartan on Cardiac Stereology in Rats with Renovascular Hypertension.

Authors:  Ali Akbar Nekooeian; Amin Rasti Pour; Farzaneh Dehghani; Elaheh Mashghoolozekr; Tahereh Esmaeilpour
Journal:  Iran J Med Sci       Date:  2021-05

9.  Blood Vessel Detection Algorithm for Tissue Engineering and Quantitative Histology.

Authors:  A Adamo; A Bruno; G Menallo; M G Francipane; M Fazzari; R Pirrone; E Ardizzone; W R Wagner; A D'Amore
Journal:  Ann Biomed Eng       Date:  2022-02-16       Impact factor: 3.934

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.